China-based firm InxMed (Nanjing) Co., Ltd has announced a strategic partnership with compatriot firm GeneQuantum Healthcare. Under the terms of the agreement, GeneQuantum will grant InxMed a non-exclusive license to utilize its independently developed and globally leading core coupling technologies for the development of innovative antibody drug conjugates (ADCs).
Access to Cutting-Edge Coupling Technologies
The technologies to be utilized by InxMed include sugar chain targeted coupling technology (iGDC), novel stable linker effector molecule technology, and intelligent continuous coupling production technology. These advancements are crucial for the development of ADCs, which are a type of precision medicine that combines the targeting ability of monoclonal antibodies with the cytotoxic properties of chemotherapeutic agents.
Enhancing InxMed’s ADC Development Capabilities
The partnership with GeneQuantum Healthcare is expected to significantly enhance InxMed’s capabilities in the development of ADCs. By leveraging GeneQuantum’s core coupling technologies, InxMed aims to accelerate the creation of new therapies that can improve treatment outcomes for patients with various diseases.-Fineline Info & Tech
